Nifurtimox

1.	Ferreira, Jorge: 1 article (05/2008)
2.	Torres, Gloria: 1 article (05/2008)
3.	Maya, Juan D: 1 article (05/2008)
4.	Orellana, Myriam: 1 article (05/2008)
5.	López-Muñoz, Rodrigo: 1 article (05/2008)
6.	Morello, Antonio: 1 article (05/2008)
7.	Faúndez, Mario: 1 article (05/2008)
8.	Kemmerling, Ulrike: 1 article (05/2008)
9.	Forman, Edwin: 1 article (10/2006)
10.	Saulnier Sholler, Giselle L: 1 article (10/2006)

Related Diseases

1.	Chagas Disease (American Trypanosomiasis) 04/01/2003 - "Nifurtimox has been used successfully in the treatment of American trypanosomiasis, or Chagas disease, but only in small studies or as a compassionate use treatment" 01/01/2002 - "The aim of the present study was to study the trypanocidal activity of nanoparticles loaded with nifurtimox in comparison with the free drug against Trypanosoma cruzi, responsible for Chagas' disease" 05/01/1998 - "In this study nifurtimox use prevented this increase, and we suggest that in immunocompromised patients with chronic Chagas' disease the use of this drug could be useful." 01/01/1998 - "The aim of this study was to evaluate the utility of nanoparticles of polyalkylcyanoacrylate as a targeted delivery system for nifurtimox against Trypanosoma cruzi, responsible for Chagas' disease" 03/01/1975 - "Clinical therapeutic trial in chronic Chagas' disease using nifurtimox in 3 schedules of long duration]" Order ALL the reference details at left...
2.	Infection 07/01/1977 - "Evaluation of the efficacy of nifurtimox in chronic human chagasic infection by using xenodiagnosis (author's transl)]" 09/01/2003 - "Nifurtimox treatment of chronic Chagasic infection in children]" 04/01/2000 - "cruzi infection results in profound alterations of the hematopoietic system and that these alterations can be prevented by nifurtimox treatment." 04/01/2000 - "More importantly, none of blood and bone marrow alterations were observed in nifurtimox-treated animals when treatment was initiated early in infection, one or seven days postinoculation" 01/01/1991 - "1. Nifurtimox uptake and metabolism by epimastigote forms of three strains of Trypanosoma cruzi (Basileu, Y, YuYu) with different drug responsiveness in mice experimental infections were compared" Order ALL the reference details at left...
3.	Parasitemia 04/01/2000 - "Administration of nifurtimox, a trypanocydal drug currently in clinical use at different days postinfection, modulates parasitemia and prevents mortality" 02/01/1988 - "Nifurtimox-treated chagasic animals injected with 2,500 trypomastigotes developed higher parasitemia and increased mortality compared with nontreated chagasic mice" 01/01/1996 - "Benznidazole proved to be better tolerated and more effective in the management of parasitemia when compared to nifurtimox, although more effective and less toxic drugs are still desirable." 01/01/1985 - "Lampit or Ethidium treatment eliminated bloodstream and kidney forms when administration was initiated after the development of patent parasitemias" 01/01/2000 - "In this study is presented the comparative therapeutical experience comparing the Allopurinol, Benznidazol y Nifurtimox, in a prospective following in a long term, considering the responses to the parasitemia, specific serology and evolution of the clinic manifestations and complementaries in the 535 chronic chagasic cases (44.5%), instead of 668 patients who did not get any treatment (1203 chagasic cases followed for more than 5 years average)" Order ALL the reference details at left...
4.	Toxoplasmosis 10/01/1998 - "The doses of nifurtimox used in the present study were not significantly effective against murine toxoplasmosis" 10/01/1998 - "In the search for novel antitoxoplasmic agents, we evaluated the efficacy of nifurtimox (3-methyl-4[5'-nitrofurfurylidene-amino]-tetrahydroe-4H-1,4- thiazine-1,1-dioxide), an antiprotozoal drug effective against trypanosomiasis, in an experimental model of acute toxoplasmosis in mice" 10/01/1998 - "Nifurtimox plus pyrimethamine for treatment of murine toxoplasmosis." 08/01/1990 - "Drugs considered include cotrimoxazole (trimethoprim + sulfamethoxazole), pentamidine, dapsone (diaphenylsulfone), trimetrexate, eflornithine (DFMO), and primaquine/clindamycin and pyrimethamine/sulphonamide combinations for Pneumocystis pneumonia; pyrimethamine/sulfadiazine, spiramycin, and clindamycin for toxoplasmosis; pentavalent antimonials ('Pentostam' and 'Glucantime'), pentamidine, amphotericin B, allopurinol, ketoconazole, and itraconazole for leishmaniasis; suramin, pentamidine, melarsoprol, tryparsamide, Mel W, berenil, and eflornithine (DFMO) for African trypanosomiasis; and nifurtimox, benznidazole and gentian violet for American trypanosomiasis." Order ALL the reference details at left...
5.	Trypanosomiasis 01/01/1992 - "DFMO is not very active in rhodesiense sleeping sickness and experience with nifurtimox in this form of trypanosomiasis is too limited to draw valid conclusions" 10/01/1998 - "In the search for novel antitoxoplasmic agents, we evaluated the efficacy of nifurtimox (3-methyl-4[5'-nitrofurfurylidene-amino]-tetrahydroe-4H-1,4- thiazine-1,1-dioxide), an antiprotozoal drug effective against trypanosomiasis, in an experimental model of acute toxoplasmosis in mice" 02/01/2007 - "We here discuss the use of current drugs against human and veterinary African trypanosomiasis, the prevalence, causes and mechanisms of drug resistance and new developments in trypanosomiasis therapy such as the introduction of nifurtimox and DB289." 06/01/1991 - "In trypanosomiasis chemotherapy the main mode of action of the nitro-compounds, including the 5-nitroimidazoles or nitrofurans (nifurtimox) is to increase the oxidative stress on the organism either directly by the production of peroxides or indirectly by "futile redox cycling"" 07/01/2002 - "Additional research and development efforts must be made for the development of new compounds, including: testing combinations of current trypanocidal drugs, completing the clinical development of nifurtimox and registering it for trypanosomiasis, completing the clinical development of an oral form of eflornithine, pursuing the development of DB 289 and its derivatives, and advancing the pre-clinical development of megazol, eventually engaging firmly in its clinical development" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Nifurtimox
2.	benzonidazole (benznidazole)
3.	Primaquine
4.	Melarsoprol (Mel B)
5.	Eflornithine (Ornidyl)
6.	Allopurinol (Remid)
7.	Chloroquine (Aralen)
8.	MK 436
9.	Suramin (Suramin Sodium)
10.	Ketoconazole (Nizoral)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Therapeutics

Best Treatments:
Research Summary Report
on Chagas Disease

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 74 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>